Investment Rating - The investment rating for the industry is "Outperform the Market" [1][4]. Core Views - The report indicates that Amer Sports has shown strong performance in Q3 2025, with revenue and profit exceeding previous guidance and Bloomberg consensus expectations. The growth is driven by the Salomon brand, DTC channels, and strong performance in Greater China and the Asia-Pacific region. Management has raised the full-year revenue, profit margin, and EPS guidance [2][3][34]. Summary by Sections Financial Performance - For Q3 2025, Amer Sports reported a revenue increase of 30% year-on-year to $1.756 billion, with adjusted net profit rising 161% to $185 million. The adjusted gross margin improved by 2.4 percentage points to 57.9%, and the adjusted operating margin increased by 1.3 percentage points to 15.7%, surpassing Bloomberg consensus expectations [2][7][8]. - Revenue growth was driven by all three business segments, with Technical Apparel up 31%, Outdoor Performance up 36%, and Ball & Racquet up 16%. The Greater China region saw a revenue increase of 47% [2][18]. Management Guidance - Management has raised the full-year revenue growth forecast to 23-24%, with an expected contribution of 100 basis points from exchange rates. The adjusted gross margin is now projected to be around 58%, and the adjusted operating margin is expected to be between 12.5% and 12.7% [32][33]. Business Segment Performance - Technical Apparel: Revenue increased by 31% (fixed exchange rate +32%), driven by strong performance in all regions and channels, particularly in women's products [15]. - Outdoor Performance: Revenue grew by 36% (fixed exchange rate +32%), with significant contributions from footwear and apparel. The DTC channel saw a 67% increase [16]. - Ball & Racquet: Revenue rose by 16% (fixed exchange rate +16%), primarily driven by strong sales in apparel and the tennis segment [17]. Regional Performance - Revenue growth by region: Greater China +47%, Asia-Pacific +54%, North America +12%, and EMEA +23%. All business lines performed well across these regions [18]. Channel Performance - DTC channel revenue increased by 51% to $720 million, accounting for 41% of total revenue, while wholesale revenue grew by 18% [18].

Core Insights - The company reported strong sales growth and increased profit margins, leading to improved profitability in Q3 2025 [1][5]. Financial Performance - Revenue for Q3 2025 reached SEK 784.1 million, marking a 47% increase compared to SEK 532.8 million in the same period last year, with a 53% growth in local currencies [1][5]. - EBITDA rose to SEK 109.7 million from SEK 63.0 million, resulting in an EBITDA margin increase to 14.0% from 11.8% [1][5]. - Gross profit was SEK 277.2 million, with a gross profit margin of 35.4%, up from 33.6% [5]. - Net profit for Q3 was SEK 89.4 million, compared to SEK 42.6 million in the previous year [5]. - Cash flow from operating activities for Q3 was SEK 136.6 million, significantly higher than SEK 36.9 million in the same quarter last year [5]. Year-to-Date Performance - For the first nine months of 2025, total revenue was SEK 2,302.2 million, a 54% increase from SEK 1,494.3 million [5]. - Year-to-date EBITDA was SEK 268.2 million, with an EBITDA margin of 11.6%, slightly down from 11.9% [5]. - Net profit for the first nine months was SEK 200.9 million, compared to SEK 126.1 million in the same period last year [5]. - Cash flow from operating activities for the year-to-date was SEK 270.4 million, up from SEK 128.3 million [5]. Strategic Developments - The company acquired assets from US-based direct sales companies Bod Pro and Truvy to enhance distribution capabilities in North America, Latin America, South Korea, and Japan [1]. - The acquisition of 35% of shares in Xion International Group was initiated to further develop its own-produced omega-3 oil and spirulina [7].

Summary of Baxter International Conference Call Company Overview - **Company**: Baxter International (NYSE:BAX) - **Date**: November 18, 2025 - **Key Speakers**: Joel Grade (CFO), Kevin Moran (Investor Relations) Key Points Industry and Company Changes - Baxter has undergone significant portfolio management, divesting non-core businesses to focus on core operations [3][4] - The acquisition of Hillrom in December 2021 led to increased debt and integration challenges, prompting strategic changes in January 2023 [4][5] - Key divestitures included the BPS (contract manufacturing) and kidney businesses, aimed at debt reduction and strategic alignment [4][5] Financial Performance and Growth Strategy - The company aims to stabilize operations and improve cash generation for reinvestment in growth [6][8] - Baxter's current focus is on enhancing operational consistency and predictability, with no major portfolio changes anticipated in the near term [6][8] - The advanced surgery business within the MPT segment grew by 11% last quarter, indicating strong performance [11] Segment Performance - **MPT Segment**: - Challenges with the Novum pump, but the Spectrum pump remains a strong alternative [9][10] - Fluid conservation efforts have reset the baseline for growth, with expectations for continued growth in this area [10][26] - **HST Segment**: - Positive order book with a 30% increase year-over-year, indicating strong demand [11] - Anticipated modest growth in frontline care markets [12] - **Pharmaceutical Segment**: - Compounding is a fast-growing area, although it has lower margins [12] - Anesthesia business showed high single-digit growth, but challenges remain in the U.S. injectables market due to market shifts [12][13] Future Outlook - Baxter plans to provide more detailed guidance and a long-range plan update in 2026 [14] - The company is focused on new product launches, including the Connex 360 monitor, which is expected to enhance margins in the future [16][17] - Ongoing efforts to improve margins through cost efficiencies and product mix optimization [18] Regulatory and Market Challenges - The Novum pump's market re-entry is uncertain, with expectations that it may extend beyond 2025 [21][22] - Baxter is actively engaging with regulators to ensure compliance and safety during the Novum pump's return process [22] - The company is managing tariff impacts, with a net impact of approximately $40 million, and is focusing on targeted pricing actions to mitigate these effects [32][34] GPO Contracts and Pricing Strategy - Baxter renegotiated two of three large GPO contracts, resulting in an anticipated 100 basis points price increase at the enterprise level [30] - The third GPO contract will be renegotiated in late 2026, impacting 2027 pricing [31] Conclusion - Baxter is navigating a complex landscape of operational challenges and market dynamics while focusing on core business growth and strategic realignment. The company is committed to enhancing its product offerings and operational efficiencies to drive future growth and profitability [40]

Core Insights - Team, Inc. (TISI) shares have decreased by 6.3% following the third-quarter 2025 results, contrasting with a 1.9% decline in the S&P 500 index, although the stock has increased by 11.4% over the past month, indicating improved investor sentiment [1] Financial Performance - Revenues for the quarter rose by 6.7% year-over-year to $225 million, with gross margin expanding by 8.4% to $58 million, and adjusted EBITDA increasing by 28.6% to $14.5 million, leading to a margin improvement of 110 basis points [2] - The net loss was reported at $11.4 million, slightly higher than the $11.1 million loss from the previous year, with earnings per share reflecting a loss of $2.68 compared to a loss of $2.52 last year [2] Segment Performance - The Inspection & Heat-Treating (IHT) segment generated revenues of $113.8 million, a 5.7% increase, driven by higher service activity in the U.S. and an 8.9% increase in international markets [3] - The Mechanical Services (MS) segment saw revenues improve by 7.8% to $111.2 million, supported by stronger U.S. turnaround activity and better results in Canada, with operating income rising by 31.2% to $5.9 million [3] Cost Management - Adjusted selling, general and administrative expenses decreased to 20.8% of revenues from 21.7% in the prior-year quarter, indicating progress in cost control, although corporate expenses increased due to non-recurring legal fees, compressing consolidated operating income to $1.3 million from $3.2 million [4] Management Commentary - Management noted that adjusted EBITDA reached its highest level for a third quarter since at least 2016, with growth in adjusted EBITDA outpacing revenue gains, reflecting successful cost-reduction and margin-expansion initiatives [5] - The company is focused on maintaining cost discipline, enhancing commercial execution in higher-margin markets, and expanding wallet share among existing customers, with ongoing improvements in margin and cost structure simplification [6] Revenue Drivers - Revenue growth was primarily driven by volume gains in both core segments, with IHT benefiting from increased U.S. activity and international work, while MS saw elevated demand in the U.S. and improved Canadian activity [7] Cost Factors - Margin improvements were attributed to field cost rationalization and a better project mix, although consolidated operating income contracted due to higher non-recurring corporate expenses [8] Guidance - Management expects full-year 2025 revenue growth of approximately 5% and adjusted EBITDA growth of roughly 13%, with anticipated year-over-year gains in the fourth quarter and further improvements in international operations [10] Other Developments - Team completed a $75 million private placement of preferred stock, using proceeds to reduce total debt from $325.1 million to $302.8 million, enhancing liquidity and financial flexibility [11]

Core Viewpoint - Ctrip Group's stock price has experienced a decline of over 6%, currently down 4.17% at HKD 552.5, with a trading volume of HKD 1.316 billion, following travel advisories against visiting Japan [1] Group 1: Market Reaction - Ctrip's stock fell sharply after the Chinese government issued warnings to citizens to avoid travel to Japan, leading to a significant number of hotel cancellations [1] - The company's customer service indicated that they are actively managing cancellations and assisting customers with refunds, with some hotels agreeing to free cancellations [1] Group 2: Business Performance - Goldman Sachs reported that Ctrip's outbound travel business is normalizing, with a year-on-year growth of 14-15%, slightly above the company's guidance of 10-20% [1] - According to Guotai Junan Securities, Ctrip is benefiting from economies of scale in R&D and management expenses, with adjusted profit margins on an upward trajectory [1] - Profitability is expected to improve further with the anticipated earnings recovery of Trip.com [1]

公司公布3Q25 业绩：收入76.9 亿元，同增5%，超我们预期（76.1 亿元）；Non-GAAP 净利润7.87 亿 元，超我们预期（5.63亿元），我们判断主要因广告收入增速高，毛利率好于此前预期。 发展趋势 利润率提升趋势向好，广告业务增势驱动明显。公司3Q25 广告收入同增23%至25.7 亿元；毛利率环增 0.2ppt 至36.7%；经调整净利率环增2.6ppt 至10.2%。我们认为：1）公司3Q25 广告收入高增速助力驱动 毛利率提升，主要得益于效果广告eCPM 的持续提升和品牌广告的快速增长；2）伴随商业化成熟，公 司中长期利润率提升趋势整体向好，营收增长、营收结构改善和经营杠杆释放或共同助力。我们判断， 公司4Q25 广告收入或同增23%至29.3 亿元，2026 年增速有望保持行业领先，后续重点关注多屏多终端 广告场景释放潜力；4Q25 公司毛利率有望达37%，调整后营业利润率有望达9%。公司于业绩会表示， 中期毛利率目标为40~45%，调整后经营利润率目标为15~20%。 机构：中金公司 研究员：张雪晴/白洋/焦杉/肖俨衍/魏萌 业绩回顾 3Q25 Non-GAAP 净利润高于我们预期 ...

Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Views - The company is expected to see a recovery in cotton sock sales as it gradually expands its high-quality customer base and depletes existing inventory. The seamless management is also anticipated to improve profitability, with expectations for customer expansion and volume growth to drive an elastic growth curve. Excluding asset disposal gains, the projected net profit attributable to shareholders for 2025-2027 is estimated at 310 million, 360 million, and 400 million yuan, representing year-on-year changes of -4%, +14%, and +12% respectively. The corresponding price-to-earnings ratios are 13, 12, and 11 times, with a dividend yield of 4.5% based on a 60% payout ratio [2][4][11]. Financial Performance Summary - In Q3 2025, the company achieved revenue, net profit attributable to shareholders, and net profit excluding non-recurring gains of 715 million, 167 million, and 102 million yuan, with year-on-year changes of -5.2%, +71.2%, and +7.3% respectively. The increase in non-recurring gains was primarily due to significant gains from the disposal of non-current assets [4][11]. - The report highlights that the gross margin improved by 3.3 percentage points year-on-year and 2.4 percentage points quarter-on-quarter to 31.8% in Q3 2025, driven by improved gross margins in both cotton socks and seamless products. The net profit margin excluding non-recurring gains increased by 1.7 percentage points year-on-year, although the increase was less than that of the gross margin due to a rise in management and sales expense ratios [11][18].

Results Presentation 3Q2 5 The ecosystem of solutions created to simplify Brazil's healthcare market Opening Remarks CEO: Leonardo Byrro Priorities Established for 2025 Working Capital Quality x Quantity Operational Excellence Operational Excellence: Expected Improvements 4 ▪ Adjustment of operations with a focus on efficiency and cash generation, reducing the pace of growth. ▪ Discontinuation of businesses with below-expected returns (ROIC) and margin expansion across all business lines. ▪ Reduction of exp ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $567 million, down $34 million year-over-year, primarily due to increased accounts receivable cleanup of approximately $20 million [11] - Adjusted EBITDA was $243 million for the quarter, reflecting a margin of 42.9%, which was up 60 basis points sequentially from Q2 [12] - Adjusted free cash flow in the quarter was $122 million, representing a 22% margin or $0.67 per share [15] Business Line Data and Key Metrics Changes - Leasing revenues were $434 million in Q3, a 5% year-over-year decline, but only down 1.3% when excluding write-offs related to accounts receivable cleanup [12][13] - Sales in new and rental units increased by 10% year-over-year [11] - VAPS revenues were flat year-over-year despite volume headwinds, while storage portfolio saw a 10% improvement in rate and mix, partially offsetting a 14% volume decline [13] Market Data and Key Metrics Changes - The Canadian market experienced a slowdown, contributing to a revenue decline of approximately $130 million [35] - The company noted that traditional storage business remains weak, while climate-controlled storage units on rent were up 44% year-over-year [50] Company Strategy and Development Direction - The company aims to shift revenue towards more differentiated, higher-value offerings to create consistent results and reduce variability from commoditized lines of business [6][8] - A multi-year network optimization plan is underway to enhance operational efficiency and reduce structural costs, with an estimated net book value of rental fleet units for disposal between $250 million and $350 million [19][18] - The focus is on reestablishing organic growth through local market initiatives and enterprise accounts, with expectations for enterprise accounts revenue to grow approximately 5% year-over-year in the second half [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the need for a more conservative approach to guidance to minimize the risk of negative surprises, emphasizing accountability and credibility [8][9] - The company expects Q4 2025 revenue of approximately $545 million and adjusted EBITDA of approximately $250 million, with a full-year 2025 revenue outlook of around $2.26 billion [20] - Management expressed optimism about the potential for growth in the enterprise portfolio and value-added products, despite challenges in the traditional storage market [23][26] Other Important Information - The company has paid down $84 million in borrowings and returned $21 million to shareholders through repurchases and dividends [16] - A review of real estate positions is ongoing to reduce the real estate footprint while maintaining market coverage, with real estate costs having increased by over 10% per year [17] Q&A Session Summary Question: Inquiry about revenue outlook and underperformance - Management identified seasonal storage components and write-off activities as significant contributors to lower revenue outlook, with the Canadian market also underperforming [34][35] Question: Impact of federal government shutdowns - Management reported negligible disruption from government shutdowns, maintaining enthusiasm for future opportunities in government sectors [39] Question: Clarification on fleet review and potential disposals - Management clarified that the fleet being reviewed for disposal represents about 10% of total fleet, primarily excess units not needed for future growth [44][45] Question: Trends in order book and activations - Management noted that the modular order book is down about 1% year-over-year, with activations showing low single-digit growth recently, while traditional storage remains weak [50] Question: Changes in guidance philosophy - Management emphasized a shift towards conservative guidance to avoid negative surprises, focusing on controllable outcomes [86][87]

Financial Data and Key Metrics Changes - Underlying revenue growth for Q3 2025 was 5%, consistent with H1 run rate, with reported revenue at $1.5 billion, reflecting a 6.3% increase due to a 130 basis point tailwind from foreign exchange [2][5] - Free cash flow guidance raised from over $600 million to around $750 million, driven by improved working capital discipline and operational efficiencies [3][11] Business Line Data and Key Metrics Changes - Orthopedics grew 4.1% on an underlying basis, with strong performance in hips in the US offsetting softer knee sales [5][6] - Trauma and extremities grew 7.5%, with notable contributions from the Evos plating system and Atos shoulder [7] - Advanced Wound Management grew 6%, with advanced wound care growing 1.1% and Bioactives up 12.2% [8][9] Market Data and Key Metrics Changes - US market grew 5.5%, while other established markets grew 3.9% and emerging markets grew 5.4% [5] - Excluding China, underlying revenue growth was 6.4%, with joint repair growth at 13% [3][8] Company Strategy and Development Direction - Innovation remains central to growth, with over half of growth coming from products launched in the last five years [12] - The company is focused on operational improvements and cash efficiency, with plans to present a new strategy at upcoming capital markets events [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting revenue guidance for Q4, citing a strong sales funnel and new customer integrations [20][30] - The company anticipates continued margin expansion beyond 2025, despite headwinds from tariffs and reimbursement changes [11][41] Other Important Information - The company launched several new products, including the Alevi Complete Care dressing and the Legion medial stabilized knee, which are expected to drive future growth [12][14] - Management acknowledged ongoing challenges in the US knee market but remains optimistic about future performance improvements [15][27] Q&A Session Summary Question: Concerns about revenue guidance and margin expectations - Management remains confident in Q4 revenue guidance, supported by new product launches and customer integrations, and expects to maintain margin guidance in the 19-20% range [20][30] Question: Impact of portfolio rationalization on US knees - Management acknowledged the gap between their performance and market growth in US knees, attributing it to ongoing portfolio rationalization, but expressed optimism for future improvements [27][28] Question: Key factors affecting margins in 2026 - Management outlined several headwinds for 2026, including tariffs and pricing pressures, but remains confident in achieving margin expansion through operational efficiencies [41][42] Question: Future of the China business - The company is committed to building a sustainable business in China and will evaluate product lines for investment based on profitability [42] Question: Expectations for Q4 performance in other recon - Management expects a rebound in other recon performance in Q4, driven by strong placements and utilization rates [75]